Background: Indole derivatives have attracted considerable interest in medicinal chemistry due to their diverse biological activities. Despite their potential, challenges persist in optimizing these molecules for efficacy, selectivity, and safety. Computational chemistry offers a powerful toolkit to address these limitations in early-stage drug discovery. Objectives: This research investigates the design, optimization, and mechanistic profiling of novel indole-based compounds using a suite of in silico techniques. The goal is to identify potent and selective drug-like candidates with enhanced pharmacological profiles suitable for targeting various disease-associated biomolecules. Methods: A range of computational techniques was employed to assess indole-based derivatives. Pharmacokinetics [ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling], bioavailability, and drug-likeliness studies were performed using SwissADME online tool. In silico target identification tools were utilized to predict off-target interactions. Results: The evaluation of novel indole-based derivatives through comprehensive in silico techniques revealed several promising candidates with favorable pharmacokinetic and safety profiles. SwissADME analysis indicated high oral bioavailability, good gastrointestinal absorption, and optimal drug-likeness scores for the top-performing compounds. ADMET profiling confirmed acceptable absorption, distribution, and metabolic stability, while predicting minimal toxicity risks. Conclusions: This study underscores the effectiveness of integrated computational approaches in evaluating the pharmacological and toxicological potential of indole-based derivatives. The use of SwissADME and other in silico tools facilitated a detailed assessment of ADMET properties, bioavailability, and drug-likeness leading to the identification of safe and potent lead compounds. These findings establish a strong foundation for experimental validation and development of indole derivatives as therapeutic agents across multiple disease domains.